Madrigal Pharmaceuticals (MDGL) Competitors

Madrigal Pharmaceuticals (NASDAQ:MDGL) and Biogen (NASDAQ:BIIB) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, analyst recommendations, dividends, community ranking, earnings, profitability, valuation, institutional ownership and risk.

Do analysts prefer MDGL or BIIB?

Madrigal Pharmaceuticals presently has a consensus price target of $351.67, suggesting a potential upside of 5.04%. Biogen has a consensus price target of $228.80, suggesting a potential upside of 58.97%. Given Biogen's higher possible upside, analysts clearly believe Biogen is more favorable than Madrigal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Madrigal Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69
Biogen	0 Sell rating(s)	16 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.43

Is MDGL or BIIB more profitable?

Biogen has a net margin of 16.81% compared to Madrigal Pharmaceuticals' net margin of 0.00%. Biogen's return on equity of 14.98% beat Madrigal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Madrigal Pharmaceuticals	N/A	-71.78%	-53.25%
Biogen	16.81%	14.98%	8.59%

Which has more volatility & risk, MDGL or BIIB?

Madrigal Pharmaceuticals has a beta of -0.36, meaning that its stock price is 136% less volatile than the S&P 500. Comparatively, Biogen has a beta of -0.07, meaning that its stock price is 107% less volatile than the S&P 500.

Which has better earnings & valuation, MDGL or BIIB?

Biogen has higher revenue and earnings than Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Madrigal Pharmaceuticals	N/A	N/A	-$373.63M	-$25.08	-13.35
Biogen	$9.84B	2.13	$1.16B	$11.07	13.00

Does the media prefer MDGL or BIIB?

In the previous week, Biogen had 34 more articles in the media than Madrigal Pharmaceuticals. MarketBeat recorded 52 mentions for Biogen and 18 mentions for Madrigal Pharmaceuticals. Madrigal Pharmaceuticals' average media sentiment score of 0.55 beat Biogen's score of 0.32 indicating that Madrigal Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Madrigal Pharmaceuticals	7 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Biogen	18 Very Positive mention(s)	4 Positive mention(s)	9 Neutral mention(s)	8 Negative mention(s)	3 Very Negative mention(s)	Neutral

Does the MarketBeat Community prefer MDGL or BIIB?

Biogen received 1351 more outperform votes than Madrigal Pharmaceuticals when rated by MarketBeat users. Likewise, 71.71% of users gave Biogen an outperform vote while only 67.80% of users gave Madrigal Pharmaceuticals an outperform vote.

Company	Underperform	Outperform
Madrigal Pharmaceuticals	Outperform Votes 459 67.80%	Underperform Votes 218 32.20%
Biogen	Outperform Votes 1810 71.71%	Underperform Votes 714 28.29%

Do institutionals and insiders hold more shares of MDGL or BIIB?

98.5% of Madrigal Pharmaceuticals shares are held by institutional investors. Comparatively, 87.9% of Biogen shares are held by institutional investors. 22.8% of Madrigal Pharmaceuticals shares are held by insiders. Comparatively, 0.2% of Biogen shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Biogen beats Madrigal Pharmaceuticals on 13 of the 17 factors compared between the two stocks.